12:00 AM
 | 
May 18, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Myeloid Progenitor: Phase I started

Cellerant began the open-label, dose-escalation, U.S. Phase I IND trial to evaluate 2 dose levels of intravenous CLT-008 given 24 hours after cord blood transplantation in 20-25 patients....

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >